Skip to main content
CDC Website

Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed)

The scientific objective of this Funding Opportunity Announcement is to encourage research to delineate the role of inflammasomes in the neuropathology produced by acute or chronic drug exposure and HIV infection. Understanding the involvement of inflammasomes in virus and drug-induced immune activation may help identify molecular markers and CNS immune cells associated with HIV-1 infection or disease progression among substance abuse populations, as well as identify novel therapies to target inflammasome activation or suppression to treat neuroinflammation and immune dysregulation aroused in these processes.

Funding ID:
RFA-DA-25-013
Application Due Date:
Application Contact
Shang-Yi Anne
Tsai, Ph.D.
Scientific/ Research Contact- NIDA
United States
301-827-5842
stsai@nih.gov
Technical Contact
Juliette
Lee
Financial/Grants Management Contact, NIDA
301-402-7744
nathanic@nida.nih.gov
Funding Organization:
The US Department of Health and Human Services National Institutes of Health
  • HIV/AIDS
  • Other Health-Related
  • International
  • Clinical Research
  • Data Analysis
  • Health Care Planning
  • HIV
  • HIV and AIDS Prevention
  • Research
Was this page helpful? Give Feedback